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Abstract.  Fusion of mouse L929 cytoplasts with hu- 
man peripheral blood lymphocytes induced lymphocyte 
proliferation that gave rise to lymphoid cell lines of B 
and T cell origin with unlimited growth potential. The 
immortalized cell lines were routinely grown in stan- 
dard medium supplemented with fetal calf serum. Fur- 
thermore these cell lines could be propagated in chem- 
ically defined serum-free media. Each establishment of 
lymphoid cell lines was preceded by a proliferation 
phase 2 wk after cytoplast/cell fusion, which appears 
to be a necessary step in the immortalization process. 
The immortalized cells have a nearly normal human 
karyotype, do not form colonies in soft agar medium, 
and are not tumorigenic in nude mice. Cloned B cell 
lines produced human immunoglobulins of heavy and 
light chain types. No cross-reaction with DNA of her- 
pes simplex virus, human cytomegalovirus, human T 
cell leukemia/lymphoma virus I and II, or polyoma vi- 
rus was detected in the genome of immortalized cell 
lines by Southern blot hybridization. Furthermore B 
and T cell lines were established that appear to be free 
of Epstein-Barr virus genome. 
T 
rl~.  mechanisms  by  which  normal  somatic  cells 
acquire unlimited proliferation potential are not fully 
understood.  The conversion of mammalian cells with 
limited life span to permanent proliferation is considered to 
be  an important  step  in the progression  from normal to 
malignant phenotype. It has been suggested (24, 25) that cer- 
tain oncogenes ("immortalizing genes") may separately or in 
combination influence cellular functions that drive the cell 
to  divide  autonomously  or  in  response  to  self-secreted 
growth-promoting  factors (autocrine growth control). 
Normal human lymphocytes from peripheral blood are qui- 
escent cells with limited life span in vitro that enter S-phase 
only if stimulated differently, resulting in clonal proliferation 
and maturation. Resting B cells can be activated to a prolifer- 
ating stage by mitogens, by B cell growth factors, or via a 
pathway that requires T cell recognition of  B cells and acces- 
sory cells. Upon recognition of their specific antigen, acti- 
vated helper T cells release  a variety of lymphokines and 
hemopoietic growth factors (30). Long term cultures of nor- 
mal lymphocyte subpopulations have been established that 
are dependent  for proliferation  on appropriate  growth fac- 
tors,  e.g.,  B  cell  growth  factor  (28) or anti-IgM  (27) in 
the case of human B cells, and T cell growth factor (14) in 
the case of T cells. In the absence of appropriate  antigens 
or growth  factors,  these  lymphocyte populations  undergo 
senescence. 
The only known human B cell mitogen independent of ac- 
cessory  ceils  for its  action  is  Epstein-Barr  virus  (EBV)  ~ 
1. Abbreviations  used in this paper:  CMV,  cytomegalovirus;  DME, Dul- 
becco's modified Eagle's medium; EA, early antigen; EBNA, Epstein-Barr 
nuclear antigen; EBV, Epstein-Barr virus; HSA,  human serum albumin; 
which, after in vitro infection, immortalizes and transforms 
a subpopulation of  human B lymphocytes. Only C3 receptor 
carrying B cells (33) can be infected by EBV. Like EBV, hu- 
man T cell leukemia/lymphoma virus (HTLV) can transform 
normal lymphocytes in vitro to a stage of  unlimited prolifera- 
tion potential. Immortal T cell lines have been obtained by 
infection with both HTLV-I  and HTLV-II (34, 44). Although 
B lymphocytes (5) and some nonlymphoid cells (6) can also 
be infected with HTLV, OKT4  + T  cells  appear  to be the 
most permissive cells for viral replication and transforma- 
tion. However, certain T cell lines remain T cell growth fac- 
tor dependent upon HTLV infection. 
In this paper, we describe a method for establishing human 
lymphoid cell lines of  both B and T cell origin. Human lym- 
phocytes were  fused with isolated cytoplasts from mouse 
L929 cells. This procedure yielded lymphocyte populations 
6-8 wk after fusion that can be routinely grown in standard 
medium or alternatively  in chemically  defined serum-free 
media without addition of hemopoietic growth factors. We 
isolated  human B  and  T  cell  lines  that appear  to  grow 
indefinitely without expressing the malignant phenotype. 
Materials and Methods 
Cells and Cell Lines 
Mouse L929 cells were routinely grown in Dulbecco's  modified  Eagle's 
medium (DME) supplemented with 4 mM L-glutamine and 10% fetal calf 
HSV, herpes simplex virus; HTLV, human T cell leukemia/lymphOma  vi- 
rus; PEG, polyethylene glycol; PWM, pokeweed mitogen; VCA, viral cap- 
sid antigen. 
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mouse embryos. Briefly the embryos were dissected, incubated with col- 
lagenase (0.1 U/ml, Boehringer Mannheim GmbH, Manniaeim, FRG) and 
dispase (0.8 U/ml, Boehringer Mannlaeim  GmbH) in PBS for 1 h at 37°C, 
and washed twice in PBS. The cells were cultured in DME, supplemented 
with4 mM  L-glutamine, I  mM  pyruvate,  15  mM  Hepes buffer,  pH 7.2,  and 
20% fetal  calf  serum. 
Lymphoid cell  lines  Raji  (ATCC CCL 68),  B95-8 (ATCC CRL  1611), 
and Molt-4 (ATCC CRL 1582)  were grown in  RPMI 1640 medium, 4 mM 
L-glutamine, and 10% fetal  calf  serum. 
Lymphocyte Isolation 
Peripheral blood was collected from healthy adults, heparinized, and diluted 
1:2 in 3 mM citric acid, 100 mM dextrose, 70 mM NaC1, 30 mM sodium 
citrate, pH 6.1. The lymphocytes were separated according to B~yum (3) 
by centrifugation in a Metrizoat (Nyegaard Co., Oslo) gradient at 400 g for 
35 min. After washing three times in PBS the lymphocytes were cultured 
in RPMI 1640 medium, 4 mM L-glutamine,  1 mM pyruvate, 1 mM oxala- 
cetic acid, 0.1 U/ml insulin, 10 ttg/ml transferrin, 15% fetal calf serum at 
37°C in a humid atmosphere with 5% CO2. For serum-free culture, lym- 
phocytes were grown in Iscove's modified DME supplemented with SFM-2 
(Boehringer Mannheim GmbH) or alternatively in HB 104 (New England 
Nuclear, Braunschweig, FRG). Both media were supplemented with human 
serum albumin (HSA; 0.5  ttg/ml), pyruvate (1  raM),  oxalacetic acid (1 
mM), insulin (0.1 U/ml), transferrin (10 Ixg/ml),  and Hepes (30 mM). 
B and T lymphocytes were separated by affinity chromatography using 
monoclonal anti-human-pan B cell or anti-human-pan T  cell antibodies, 
respectively, covalenfly coupled to Sepharose. Briefly,  mouse monoelonal 
anti-human-pan B cell or pan T  cell antibodies (Miles, Bayer AG, FRG) 
were dissolved in 0.1  M  NaHCO3,  0.5  M  NaCI, pH 8.5,  and incubated 
with CNBr-aetivated Sepharose 6MB  (Pharmacia Inc.,  Piscataway,  NJ) 
(1  mg antibody/ml swollen gel) overnight at 4°C using an end-over-end 
mixer. To remove unbound antibodies the gel was washed three times for 
30 min in 0.1  M  NaHCO3,  0.5  M  NaCI, pH 8.5,  and three times for 30 
min in 0.1 M sodium acetate, 0.5 M NaC1, pH 4.5. To block the residual 
reactive groups the gel was incubated with 0.2 M glucosamine, 0.1 M so- 
dium acetate, 0.5 M NaCI, pH 4.5, for 2 h at room temperature. Finally 
the gel was washed twice with PBS containing HSA (0.2 %  ). For preparation 
of B cells,  l0  T peripheral blood lymphocytes, washed in PBS containing 
0.2 % HSA, were applied onto a column of  anti-human-pan B cell antibodies 
coupled to Sepharose (5 ml). Before elution the column was incubated for 
15 min at room temperature. The nonadherent cell fraction was ehted with 
50 mi PBS, 0.2% HSA (flow rate 2 ml/min). To recover the adsorbed cells, 
the column was incubated with 2 ml PBS, 0.2 % HSA, 10 mg/ml IgG at 370C 
without flow for 20 min, and mixed end-over-end. The B cell fraction was 
eluted with PBS, 0.2% HSA, 10 mg/ml IgG. The contamination of non-B 
cells was <2%  as estimated by indirect immunofluorescence using anti- 
human-pan B cell antibodies. The cell viability was >90% as determined 
by trypan blue exclusion test. Using anti-human-pan T cell antibodies cou- 
pled to Sepharose the T cell fraction could be separated as described for 
B calls. 
Preparation ofL929 Cytoplasts 
Exponentially growing L929 cells were trypsinized and washed twice in 
serum-free DME.  For induction of cytoplast formation, L929  cells (106 
cells/ml) were incubated in serum-flee DME containing 50 txg/ml cytocha- 
lasin B at 37°C (1). Within 90 s blebs appeared on the cell surface. Before 
the blebs could aggregate at one pole of  the cell surface, they were separated 
from the cells by vigorous vortexing for 40 s. After the cells were sed- 
imented at 100 g for 10 rain, the supernatant was centrifuged at 1,200 g for 
15 min. The cytoplast pellet was resuspended in Ficoll (12.5%, Pharmacia 
Inc.) in serum-free DME and separated from nucleated cells according to 
Wigler and Weinstein (42) using a gradient with 2 m125% Ficoll, 2 mi 17 % 
Ficoll, 0.5 ml 16% Ficoll, 0.5 ml 15% Ficoll, 2 ml 11.5% Ficoll in serum- 
free DME (from bottom to top). The suspension of cytoplasts was layered 
on top of the gradient and centrifuged at 100,000 g for 60 min at 30"C. The 
L929 cytoplasts were collected in the visible band at the 15-17% Ficoll re- 
gion and  washed twice in  DME at  1,200  g  for  15  rain.  Less than one 
nucleated cell per 1,000 cytoplasm was seen by fluorescence microscopy af- 
ter staining with Hoechst 33 258. To prevent proliferation of contaminating 
L929 cells, the cytoplast fraction was treated with mitomycin C (400 ttg/ml) 
for 15 min at 37°C. 
Immortalization Procedure 
To  induce  lymphocyte  proliferation  freshly  prepared  L929  cytoplasts 
(107/0.5 ml serum-free DME) were added to 107 human lymphocytes in 0.5 
ml serum-free RPMI 1640. The cell/cytoplast suspension was incubated at 
37"C for 15 rain and sedimented for 20 s in an Eppondorf centrifuge. The 
sediment was resusponded in  1 ml 50%  polyethyleneglycol (PEG, 4,000 
mol wt; SERVA Feinbioehemica GmbH & Co., Heidelberg, FRG), 150 mM 
Hepes, pH 7.5, prewarmed to 37"C. After 90 s 5 ml warm serum-free RPMI 
1640 medium was slowly added over a period of 5 rain. The cell/cytoplast 
suspension was washed twice in RPMI  1640, and 2.5  ×  106 cells were 
seeded in 0.5 ml RPMI 1640, 4 m_M L-glutamine, 1 mM pyruvate, 1 mM 
oxalaeetic acid, 0.1 U/ml insulin, 10 Ixg/mi transferrin, 15% fend calf serum 
per well of a 24-well microtiter plate. For the next 2 wk 50 ttl of the medium 
in each well was changed every 2 d. During the following weeks 250 gl of 
the culture medium was replaced by fresh medium twice a week. The cul- 
ture was first split 5 wk after fusion. 
To estimate the extent of cell-to-cytoplast fusion, an aliquot of L929 
cytoplasts (10  ~) was stained with Rhodamine 3]3 (10 ~tg/ml) (21) in serum- 
free RPMI 1640 for 30 rain at room temperature. The lymphocyte nuclei 
were stained with Hoechst 33 258 (30 ttg/ml serum-free RPMI 1640) for 
10 min at 37°C. After cell/cytoplast fusion only cybrids carry a fluorescent 
nucleus surrounded by a  Rbodamine 3B stained cytoplasm. The ratio of 
cybrids to nonfused cells was estimated by fluorescence microscopy. 
Cell Cloning 
Cell cloning was performed with a Cytofluorograf 50H interfaced with a 
model 2151 computer system (Ortho Diagnostic Systems Inc., Johnson & 
Johnson, Raritan, NJ) and equipped with an argon ion laser emitting 200 
mW at 488 nm.  Forward light scatter and 90  °  scatter were used to dis- 
criminate viable from nonviable cells. The flow rate was '~300 cells per sec- 
ond. The settings for sorting were deflection of one droplet per selected cell 
with rejection of coincidence over a  span of three droplets. Cloning was 
done directly into 96-well culture plates by seeding a single cell per well 
containing 0.1 ml of lymphocyte culture medium. 
The cloning  efficiency  in  semi-solid  agar  medium was determined as  de- 
scribed by MacPberson and Montagnier  (26) using a 0.5%  seaplaque 
agarose (Gibco, Grand Island, NY) base layer  and a 0.32% seaplaque 
agarose layer  in lymphocyte growth medium. After 3 wk colonics  were 
counted under a Leitz  stereo  microscope. 
Tumorigenicity 
3-d-old NIH Swiss nu/nu mice were subcutaneously inoculated with 104- 
107 cells (in  100-500  gl PBS) from exponentially growing cell cultures. 
Any tumors obtained were explanted and the cells were grown in vitro to 
verify the tumorigenic cell type. An autopsy was performed after 5 mo when 
no tumor could be detected from outside. 
Immunoglobulin Assay 
Culture supernatants were analyzed for human immunoglobulins (Ig)  by 
enzyme-linked immunosorbent assay  (BLISA).  Immunosorbent purified 
sheep antibodies to  human  IgM,  IgA,  or  IgG  (Boehringer Mannheim 
GmbH) and mouse monoclonal antibodies to human kappa- or lambda- 
chains (Seward Laboratory, Bedford, UK) were incubated in 96-well plates 
for 2 h at room temperature. The plates were coated with 1% BSA for 15 min, 
washed three times with PBS, and incubated with culture superuatants for 
1 h. Then the plates were washed three times, incubated with peroxidase- 
conjugated sheep anti-human Ig (Boehringer Mannheim GmbH), for 2 h, 
washed four times, and 2,2' azino-di-(Y-ethylbenzthiazolinsulfonate [6]) 
(Boehringer Mannbeim GmbH) as substrate was added. Color changes were 
quantified at 30  min using an automatic ELISA reader (SLT-Labinstru- 
ments, Salzburg). IgM production was measured with serial dilutions of  cul- 
ture supernatant using purified human myeloma IgM (Behringwerke, Mar- 
burg, FRG) as standard. 
Immunofluorescence 
Human B and T lymphocytes were detected by indirect inununofluorescence 
using a mouse monoclonal anti-human-pan B cell or pan T cell antibody, 
respectively (Miles). Washed lymphocytes (106 cells) were incubated with 
400 ~tl anti-human-pan B cell or pan T cell antibody (1:100 diluted in serum- 
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washed and  incubated with  fluorescein isothioeyanate-conjugated anti- 
mouse  IgG1 (affinity-purified,  1:100 diluted  in  serum-free RPMI  1640; 
Miles) for 30 rain at 4°C. Fimdly the cells were washed twice in PBS and 
examined by fluorescence microscopy. Cells of the B cell line Raji and of 
the T cell line Molt-4 served as controls. 
Epstein-Barr nuclear antigen (EBNA) was assayed by anti-complement 
immunofluorescence as described by Reedman and Klein (36). The EBV- 
associated early antigen (EA) and the viral capsid antigen (VCA) were tested 
as  described  (17, 18). B95-8  cells  (EBNA  +,  EA  +,  VCA+),  Raji  cells 
(EBNA  +, EA  +, VCA-), and Molt-4 cells (EBNA-, EA-, VCA-) served as 
controls. 
Chromosome Analysis and Measurement of 
Total DNA Content 
Metaphase chromosomes of cells in exponential growth phase were stained 
uniformly or differentially (Giemsa banding) according to standard tech- 
niques (43).  A  minimum of 50 metaphases were recorded for each in- 
dividual cell line. Mouse chromosomes were assessed by differential stain- 
ing of centromeres as described by Hilweg and Gropp (19). 
Total  DNA content was measured according to  Crissman et al.  (8). 
Briefly,  cloned B and T cell lines in logarithmic growth phase were fixed 
with cold 95 % ethanol, treated with RNase A (1 mg/ml), and stained with 
propidium iodide (50 lag/nil)  for 30 rain at 40C.  DNA analysis was done 
by using a Cytofluorograf 50H. During flow cytometry, cells were excited 
at 488 nm. Red fluorescence (600 nm) from propidium iodide was recorded 
as a measure of total DNA content. Human blood lymphocytes fixed on day 
4  after lectin stimulation served as standard. 
Electron Microscopy 
Cells and cytoplasts were fixed in 2.5% glutaraldehyde in PBS for 30 rain 
at room temperature, washed overnight in 0.1 M sodium cacodylate at 4°C, 
postfixed  1 h  in  1%  OsO4,  0.1  M  sodium cacodylate,  dehydrated in  a 
graded series of acetone, and embedded in Epon 812. Sections were post- 
stained with 0.5% lead citrate before examination with a Zeiss EM 10 trans- 
mission electron microscope. 
Reverse Transcriptase  Assay 
Cell-free supernatant (15 ~tl) was incubated with 15-gl double concentrated 
reaction buffer (100 mM Tris,  pH  8.3,  40  mM dithiothreitol,  1.2  mM 
MnCl2,  120 mM NaC1,  0.1%  Nonidet P-40,  30 I.tg/ml Poly(rA).p(dT)t2.1s 
[Pharmacia Inc.], 0.2 laM dATE 0.2 laM dGTE 0.2 gM dCI"P, 1 I~M TTP) 
in the presence of 1 laCi ~t-32p-TTP (3,000  Ci/mmol; Amersham Corp., 
Braunschweig, FRG) for 1 h at 37°C.  The DNA was harvested on glass 
fiber filters (GF/C, Whatman Inc., Clifton, NJ), precipitated with cold TCA 
(5%) and washed with cold ethanol. Supernatants from Cll-IA cells (10) 
served as positive, and those from SV34-7F cells (2), as negative controls. 
Nucleotide Incorporation 
Lymphocytes (5  x  104) were cultured in RPMI 1640 medium (200 lal per 
well) in 96-well microtiter plates and labeled with 1 IK2i [methyl-3H]thy - 
midine (78 Ci/mmol; New England Nuclear) for 6 h at 37°C. After washing 
the  cells  were  harvested on  glass  fiber  filters  (Whatman  GF/C).  The 
[methyl-3H]thymidine incorporation in TCA-insoluble material was deter- 
mined  by  scintillation  spectrometry.  Each  data  point  was  obtained  in 
duplicate. 
For cell autoradiography 5  x  106 cells/ml were incubated with 5  gCi 
[methyl-3H]thymidine/ml (78 Ci/mmol; New England Nuclear) for 30 min 
at 37°C. After washing three times in PBS the cells were stained for im- 
munofluorescence. The cells were covered with autoradiographic film (Ko- 
dak AR 10) and exposed at 4°C for 25 d. 
DNA Preparations 
High molecular weight DNA was isolated from ceils by lysis in 200 mM 
Tris, 100 mM EDTA, 0.2% SDS, pH 7.2, containing 100 gg/ml proteinase 
K (E. Merck, Darmstadt, FRG). After incubation at 3"/°C for 3 h nucleic 
acids were extracted with phenol and chloroform. The RNA was degraded 
by incubation with RNase A (100 lag/ml; Boehringer Mannheim GmbH) for 
2  h at 3"/0C and the DNA was reextracted. Piasmid DNA was prepared, 
digested with restriction enzymes, and subjected to electrophoresis through 
a 0.8% seakem agarose gel (FMC Corp., Marine Coll. Div., Rockland, ME) 
according to standard methods (29). To isolate DNA fragments from a 0.8 % 
low melting agarose gel, the band was excised, an equal volume of Tris/ 
EDTA buffer was added, and the agarose was melted at 68°C for 5 min. 
DNA was extracted three times in phenol, twice in chloroform, and in ether. 
DNA fragments were blotted by Southern transfer (39) onto a Genescreen 
plus membrane (New England Nuclear) or nitrocellulose (Schleicher & 
Schueli, Inc., Keene, NH) alternatively. The membrane was prehybridized 
in  50%  formamide, 0.2%  polyvinylpyrrolidone (40,000  mol wt), 0.2% 
BSA, 0.2% Ficoll (400,000  mol wt), 0.05 M Tris, pH 7.5, 1 M NaCI, 0.1% 
sodium pyrophosphate, 0.1%  SDS,  10% dextransulfate (500,000  mol wt), 
250 lag/ml salmon sperm DNA at 42"C for 24 h. Isolated DNA restriction 
fragments were labeled with 32p by nick translation (29) to specific activi- 
ties  of  107-10  a  cpm/Ixg  DNA.  The  hybridization was  carried  out  with 
100 ng labeled DNA at 42°C for 48 h in the prehybridization buffer (2  x 
106 cpm/mi). The membrane was twice washed in 2 x  standard saline ci- 
trate (SSC), 0.1% SDS for 15 min at room temperature, and twice in 0.1x 
SSC, 0.1% SDS for 30 min at 52°C. The autoradiograph was exposed for 
24 h at -80"C using intensifying screens (Titan 2HS, Siemens-AUis Inc., 
Cherry Hill, NJ). 
Results 
Human lymphocytes from the peripheral  blood of healthy 
adults  were  mitogenically  stimulated  by  incubation  with 
pokeweed mitogen (PWM)  1 d after isolation.  After 3-6 d 
[3H]thymidine  incorporation  reached  the  first  maximum, 
which is called proliferation phase I (Fig. 1). Nonstimulated 
lymphocytes remain quiescent in vitro as shown by [3H]thy- 
midine incorporation  using parallel cultures  supplemented 
with 20%  autologous  serum  as control.  At day 5  PWM- 
stimulated  and  nonstimulated,  quiescent  lymphocytes (107 
cells each) were fused with cytoplasts from L929 cells (107 
cytoplasts each) by incubation  with  PEG.  Treatment  with 
PEG without addition of L929 cytoplasts served as control. 
In  addition  the  same  number  of  quiescent  and  PWM- 
stimulated  lymphocytes were co-cultivated  with  107 L929 
cytoplasts without PEG-mediated cytoplast/cell fusion. In all 
cases the induction of lymphocyte proliferation  was moni- 
tored  by  [3Hlthymidine  incorporation  assay  ~Fig.  1)  and 
phase-contrast microscopy (Fig. 2).  3 d after cytoplast/cell 
fusion, clusters of lymphoid cells were observe& During the 
next 5 d these clusters rapidly increased in size a~ad cell num- 
ber to '°300-500 cells per colony. This we call proliferation 
phase II. Proliferating colonies were initially mostly adher- 
ent; at later times large colonies detached and igave rise to 
small colonies that grew in suspension.  Up to 2 d after ad- 
dition  of  L929  cytoplasts,  cell  proliferation  !ceased  and 
[3H]thymidine  incorporation  decreased  possibly  due  to 
cytotoxic effects of the cytoplast fraction.  In the maximum 
of proliferation phase II, nonstimulated lymphocytes incor- 
porated  sixfold  more  [3H]thymidine  upon  PEG-mediated 
fusion  with  L929  cytoplasts,  twofold  more  upon  co- 
cultivation with L929 cytoplasts compared with control cul- 
tures  which  had  not  been  treated  with  L929  cytoplasts. 
PWM-stimulated lymphocytes increased [3H]thymidine in- 
corporation  100-fold  upon PEG-mediated cytoplast/cell fu- 
sion and 50-fold upon co-cultivation with L929 cytoplasts. 
At this time no lymphocyte proliferation could be detected 
any  more  in  parallel  cultures  not  incubated  with  L929 
cytoplasts. 
Colonies proliferating in phase II required their own con- 
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Figure  1.  Induction of lympho- 
cyte proliferation by L929 cyto- 
plast fusion monitored by pH]thy- 
midine incorporation. Lympho- 
cytes were prepared at day 0 and 
cultivated in lymphocyte growth 
medium supplemented with 20% 
autologous serum (o) or 20% fe- 
tal calf serum (e). At day 1 lym- 
phocytes were stimulated with 
PWM  (n).  At  day  3  (arrow) 
quiescent and  PWM-stimulated 
lymphocytes were fused (~7 and 
zx, respectively) or co-cultivated 
(v  and  A,  respectively)  with 
L929 cytoplasts. 
ditioned medium. At the end of  this proliferation phase, how- 
ever,  i.e.,  17-24 d after cytoplast/cell fusion, the colonies 
grew in fresh culture medium provided that they were seeded 
at high cell densities (105 cells/ml). After three to five pas- 
sages the cells could be diluted to 103 cells/nil and could be 
grown in serum-free media without addition of hemopoietic 
growth factors. Probably these cells had begun to produce 
their own growth factors which might have provided an au- 
tologous stimulus for self-renewal. 
Proliferation phase II and subsequent infinite cell growth 
was only observed in lymphocyte populations treated with 
L929 cytoplasts. The resulting cell lines have been routinely 
grown in vitro for 1 yr (180 cell doublings) without any detec- 
tion of growth arrest or senescence. Therefore we presume 
that these cell lines are  immortalized.  The maximum of 
[3H]thymidine incorporation during proliferation phase II 
and the frequency of immortalization was dependent on the 
extent of cybrid formation between  L929  cytoplasts and 
lymphoeytes (Table  I).  The rare induction of lymphocyte 
proliferation upon co-cultivation with L929 cytoplasts was 
possibly due to spontaneous cytoplast/cell fusions as moni- 
tored  by  fluorescence  microscopy  using  Rhodamine  3B 
stained cytoplasts and Hoechst 33 258 stained lymphocytes 
as described in Materials and Methods. 
In a second experiment we asked whether or not the L929 
cytoplasts were mitogenic towards B or T lymphocytes and 
whether L929 cytoplasts could immortalize B or T lympho- 
cytes. To analyze whether lymphocyte colonies in prolifera- 
tion phase II were of  B or T cell origin, parallel cultures were 
labeled with [3H]thymidine for autoradiography. The same 
cells were stained with monoclonal anti-human-pan B cell or 
pan T cell antibodies, respectively, for investigation of in- 
direct immunofluorescence. 60% of all radioactively labeled 
colonies were of T cell origin, and 40 % were of B cell origin 
(Table II). Colonies were either of B cell or T cell origin, 
suggesting that they were derived from single cells. 5-8 wk 
after cytoplast/cell fusion, rapidly proliferating lymphocyte 
cultures (cell doubling times 25-40 h) were 30-50%  of B 
cell and 30-70 % of T cell origin. B and T cell populations 
were cloned via dilution to single cells. 
To measure the mitogenic activity of the cytoplast fraction 
towards purified B cell and T cell populations, the PWM- 
stimulated lymphocyte population was preparatively sepa- 
rated at day 6 by cell affinity  chromatography on anti-human- 
pan B cell or pan T  cell antibodies, respectively, coupled 
to Sepharose. Each cell fraction was fused or co-cultivated 
with L929 cytoplasts (107 cytoplasts per 107 lymphocytes). 
7 d after addition of cytoplasts [3H]thymidine incorporation 
increased 400-fold in PWM-stimulated B cells upon PEG- 
mediated  cytoplast/cell  fusion  and  300-fold  upon  cyto- 
plast/cell co-cultivation compared with mock-treated PWM- 
stimulated B  cell cultures. In contrast PWM-stimulated T 
cells increased [3H]thymidine incorporation only sevenfold 
in  the  maximum  5  d  after  cytoplast/cell  fusion  or  co- 
cultivation (Fig. 3). The results show that the L929 cytoplast 
fraction is up to 20-fold more mitogenic towards B cells than 
towards T cells but gives rise to both B cell and T cell lines 
that grow independently from exogeneous purified growth 
factors in serum-free media. 
Now we asked whether or not immortalization could also 
be induced by fusion with cytoplasts from primary mouse 
fibroblasts of limited life span.  Therefore cytoplasts from 
BALB/c mouse embryo fibroblasts in logarithmic growth 
phase (passage 3) were obtained by incubation with cytochala- 
sin B, purified, and fused with quiescent or PWM-stimulated 
human lymphocytes at day 5  after lymphocyte isolation. 
During  the  following weeks  no  induction of lymphocyte 
proliferation could be detected by microscopic observation 
or [3H]thymidine incorporation assay,  suggesting that the 
immortalization activity is restricted to cytoplasts from cell 
lines with unlimited proliferation potential. 
Transmission electron micrographs of L929 cells used for 
enucleation showed that these cells possessed the usual fine 
structure features that characterize mammalian cells in cul- 
ture. Studies on L929 cytoplasts used for immortalization re- 
vealed a normal cytoplasm with one to three mitochondria 
per cytoplast, parts of the Golgi apparatus and the endoplas- 
mic reticulum, and numerous ribosomes. Cells of the im- 
mortalized lines of B and T cell origin showed fine structures 
indistinguishable from normal lymphocytes in vitro (Fig. 4). 
The Journal of Cell Biology, Volume 103, 1986  798 Figure 2. Immortalization of lymphocytes by L929 cytoplast fusion as observed by phase-contrast microscopy. Primary lymphocytes  (a) 
were stimulated with PWM and gave rise to proliferation phase I (b, day 4). Upon fusion with L929 cytoplasts at day 6 rapidly growing 
lymphocyte colonies were observed (proliferation phase I1) (c at day 8; d at day 12; e at day 14). 8 wk after fusion immortalized lymphoid 
cell lines were established (f). 
Table L  Dependence of [~H]Thymidine  Incorporation during Proliferation Phase H and the Frequency of 
Immortalization Events on the Extent of Cybrid Formation between L929 Cytoplasts and Lymphocytes 
l%I]Thymidine 
incorporation  at 
No. of  No. of L929  maximum of 
lymphocyms  cytoplasts added  Cyhrids  proliferative phase II 
Immortalized lymphoid 
cell clones 
%  cpm/5 x  10  ~  cells 
106  107  35.2  230,500 
10  ~  104  32.7  210,000 
10  ~  105  2.43  151,000 
10  ~  104  O. 17  10,200 
10  ~  10  3  0.07  5,700 
10  ~  102  60.01  500 
106  0  <0.01  200 
14 
12 
5 
1 
1 
0 
0 
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Lymphocyte Populations,  during Proliferation  Phase II, 
and in Immortalized Cell Lines 10 wk after Fusion with 
L929 Cytoplasts 
Primary  Proliferation  Immortalized 
lymphocytes  phase II  cell lines 
Cell type  B  T  B  T  B  T 
%  %  % 
Exp.  1  46  51  42  55  52  47 
Exp. 2  35  64  35  62  33  65 
Exp. 3  38  61  28  69  25  71 
Exp. 4  31  66  40  57  68  30 
The cell diameter varied between 80 and 140 ttm. The nu- 
cleus with fine granular chromatin contained two to three 
prominent nuclei and the cytoplasm carried numerous ribo- 
somes as well as a large endoplasmatic reticulum, indicating 
active protein synthesis of the cells. The immortalized cell 
lines exhibited morphological diversity ranging from adher- 
ent cells to free floating round cells. 
To derive monoclonal B  and T  cell lines,  lymphocytes 
were fused with L929 cytoplasts and cloned by limiting dilu- 
tion, or preferentially by single cell sorting. In a representa- 
tive experiment lymphoid cells had a cloning efficiency of 
23 % (224 clones/960 cells seeded) using single cell sorting 
at day 41 after cytoplast fusion. As tested by ELISA 41.5% 
of  the clones produced detectable amounts of  Ig:IgM-lambda 
(27.2 %), IgM-kappa (12.9%), IgG-kappa (0.9%), and lamb- 
da-chains only (0.4%). Out of 10 of the Ig-negative clones 
four expressed pan T cell marker, one expressed pan B cell 
marker,  and  five  clones  could  not  be  classified  by  im- 
munofluorescence using antibodies to human B and T  cell 
marker. 
To estimate the stability of  Ig secretion one IgM-kappa and 
two IgM-lambda producing clones were reexamined after a 
4-mo period of continuous growth. The clones tested pro- 
duced IgM at similar quantities as at the first screening. 
Five monoclonal cell lines were subjected to karyotype 
analysis. All lines had a modal number of human chromo- 
somes of 46 (range 36-50). No mouse chromosomes were 
detectable by mouse centromere staining. 
Five B cell lines and nine T cell lines were subjected to 
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Figure 3.  Induction of B and T 
lymphocyte proliferation by L929 
cytoplast fusion monitored  by pI-I]- 
thymidine  incorporation  assay. 
Lymphocytes were  prepared  at 
day 0 (o), stimulated with PWM 
at day 1 (o), and (a) co-cultivated 
(©)  or  fused  (0)  with  L929 
eytoplasts at  day  6  (arrow). A 
parallel  culture  of lymphocytes 
(b) was fractionated in B and T 
cells. The cell fractions were co- 
cultivated (B cells, o; T cells, zx) 
or fused (B cells, =; T cells, A) 
with L929 cytoplasts. 
The Journal of Cell Biology, Volume 103, 1986  800 Figure 4.  Transmission electron micrographs of a primary lymphocyte (day 3 in vitro) (a), lymphocytes incubated with L929 cytoplasts 
at day 6 (b), and mononuclear cells of immortalized cell lines (c and d) 12 wk after fusion with L929 cytoplasts. 
cytometric DNA measurement. Their histograms revealed a 
DNA content similar to that of nontransformed human blood 
lymphocytes. 
To characterize the transformed phenotype of the immor- 
talized lymphoid cell lines the cloning efficiency in soft agar 
medium and the tumorigenicity in NIH Swiss nu/nu mice 
upon subcutaneous injection were tested. As shown in Table 
HI, cells of the immortalized lines of B cell or T cell origin 
did  not  form  colonies  in  soft  agar  medium  (frequency 
~<10  -5)  like quiescent lymphoeytes. In  contrast the malig- 
nantly transformed human Burkitt lymphoma line Raji and 
the T cell leukemia line Molt-4 exhibited cloning efficiencies 
of 10.8  % and 9.8 %, respectively. Upon subcutaneous injec- 
tion in 3-d-old NIH Swiss nu/nu mice, cells of the immortal- 
ized lymphoid lines of B or T  cell origin (104-107 cells per 
mouse) did not induce tumors at the injection site nor could 
tumors be detected at autopsy 5 mo after injection (Table HI). 
When equal numbers of primary human lymphocytes were 
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Tumorigenicity in NIH Swiss nu/nu Mice of Immortalized 
Lymphoid Cell Lines of B and T Cell Origin 
Induction of 
Cell lines  Cloning efficiency  tumors/injected  mice 
% 
B-1  g0.001  0/5 
B-2  ~<0.001  0/5 
B-3  ~0.001  0/5 
T-I  g0.001  0/5 
T-2  ~<0.001  0/5 
T-3  g0.001  0/5 
Primary lymphocytes  ~<0.001  0/5 
Controls 
Raji  10.8  5/5 
Molt-4  9.8  5/5 
injected as controls no tumors were obtained.  Under the 
same conditions the human cell lines Raji and Molt-4 gave 
rise  to  vigorously  proliferating  tumors,  killing  the  host 
within 6-10 d after injection. 
Various members of herpes virus group can infect leuko- 
cytes, lymphocytes, and lymphoreticular cells,  e.g., EBV, 
herpes simplex virus (HSV), and cytomegalovirus (CMV). 
Furthermore HTLV can infect and transform human lym- 
phocytes. In addition the polyoma virus genome could be 
transferred to human lymphocytes via L929 cytoplasts. We 
have searched for the presence of these viral genomes in the 
continuously proliferating cell lines obtained in this study. 
EBV  transforms  human  lymphocytes into  proliferating 
blast cells that can be easily established in vitro as infinitely 
proliferating cell lines. In nearly all cells infected by EBV, 
the EBNA was found to be expressed (36) and in produc- 
tively infected cells the Epstein-Barr EA (18) and VCA (17) 
could be detected in the cytoplasm. The EBV DNA is present 
as multiple unintegrated molecules as well as linear mole- 
cules  integrated  into  the  chromosomal DNA  (16).  In the 
lymphoid cell lines immortalized by L929 cytoplast fusion, 
expression of EBNA  was  tested by  anti-complement im- 
munofluorescence. EA and VCA  were assayed by indirect 
specific immunofluorescence. 0-19%  of the  immortalized 
noncloned cell populations of B cell origin expressed EBNA 
dependent on the lymphocyte donor (Table IV), thus demon- 
strafing the presence of the EB viral genome in these cells. 
EA and VCA could not be detected, however. In the immor- 
talized T cell populations no expression of EBNA, EA, or 
VCA was found. Furthermore no expression of EBNA, EA, 
or VCA could be detected in primary lymphocytes and iso- 
lated  colonies of proliferation phase  1I  upon  fusion with 
L929 cytoplasts. EBNA-negative B cell clones and several T 
cell clones were tested for the presence of the EB viral ge- 
nome by Southern blot hybridization. Total cellular DNA 
was isolated, digested with Barn HI, and separated in a 0.8% 
agarose gel. Upon Southern blotting the filter was hybridized 
with the cloned 3.1-kbp Bam HI fragment W of the EBV in- 
ternal repeat sequence (15) isolated from pBR 322 sequences 
before nick translation.  Plasmid DNA (6 pg, equivalent to 
about one EBV internal repeat copy/cell or to about 0.1 EBV 
genome equivalent/cell) served as positive control. No EBV 
DNA could be detected in total lymphocyte cultures or in 
Table IV.  Expression of EBNA, EA, and VCA in 
Immortalized Lymphoid Cell Lines of B and T Cell Origin 
Monitored lmmunofluorescence 
Cell lines  EBNA  EA  VCA 
%  %  % 
B-1  5  ~<0,1  ~<0.1 
B-2  <0.1  x<0.1  ~<0.1 
B-3  3  x<0.1  ~<0.1 
B-4  19  ~<0.1  <0.1 
B-4/1  96  ~<0.1  ~<0.1 
B-4/2  <0.1  x<0.1  <0.1 
T-1  <0.1  <0.1  <0.1 
T-2  ~<0.1  x<0.1  <0.1 
T-3  ~<0.1  <0.1  ~<0.1 
T-4  <0.1  <0.1  ~<0.1 
Primary lymphocytes  ~<0.1  <0.1  <0.1 
Proliferation phase II 
B cells  ~<0.1  ~<0.1  <0.1 
T cells  ~<0.1  ~<0.1  ~<0.1 
B cell line B-4 has been subcloned  by dilution  to single cells (B-4/I, B-4/2). 
purified B and T cell colonies during proliferation phase II 
or in immortalized EBNA-negative B cell clones or in T cell 
clones (Fig. 5). This suggested that the EBV genome is un- 
likely to be involved in the immortalization of B and T cell 
clones by fusion with L929 cytoplasts. 
Since  HSV  replicates upon  infection in both  mitogen- 
stimulated B and T  lymphoeytes and in myeloid cell lines 
(22), we checked whether the HSV genome was present in 
the DNA of human lymphocytes. The HSV-2 Bgl II N-frag- 
ment is  known to  establish transformed rodent fibroblast 
lines upon DNA transfection (U).  Therefore we probed by 
Southern blot hybridization total cellular DNA isolated from 
L929 cells, primary human lymphoeytes, B and T cell colo- 
nies in proliferation phase II, and from noncloned lymphoid 
cell lines and from clones of B and T cell origin immortal- 
ized by L929 cytoplast fusion with the cloned HSV-2 Bgl H 
N-fragment isolated from pBR 322 sequences before nick- 
translation.  Plasmid DNA (12 pg, equivalent to about one 
copy/cell) digested with Bg111 served as positive control. No 
positive hybridization could be detected in DNA from L929 
cells or primary lymphocytes or from immortalized lym- 
phoid cell lines. Since the Bgl 1I N-fragment of HSV-2 is ho- 
mologous to the corresponding fragment of HSV-1 (U),  we 
can also exclude that the HSV-1 genome is involved in the im- 
mortalization process of human lymphocytes by fusion with 
L929 cytoplasts. 
Human CMV causes latent, nonproductive infections in 
lymphoid ceils (41) harboring the CMV genome (20). Trans- 
fections of rodent cells with overlapping cloned fragments of 
the CMV genome (strain AD 169) identified a transforming 
490-bp fragment near the right end of the genome (32). By 
Southern blot hybridization with the cloned probe of the 
transforming region (pCM 5018) (31) we could not detect any 
hybridization with the cellular DNA of the  immortalized 
lymphoid cell lines of B cell or T cell origin or with DNA 
from L929 cells, lymphocytes in proliferation phase II upon 
fusion with L929 cytoplasts or primary lymphocytes. Plas- 
mid DNA (4 pg, equivalent to about one copy/cell) served 
as positive control. 
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these cell lines. No reverse transcriptase activity could be de- 
tected in  the  supernatant  of the immortalized human  cell 
lines tested, showing that no retroviruses were produced by 
these cells. 
Figure  5.  Southern blot hybridization of EBV internal repeat se- 
quence with DNA of lymphoid cells. Cellular DNA (15 ~tg) was 
digested with Barn HI, separated in a 0.8% agarose gel, transferred 
to a nitrocellulose filter, and hybridized with the cloned 3.1-kbp 
Barn HI fragment W of EBV internal repeat sequence (15) isolated 
from pBR 322 DNA before nick-translation (10  s cpm/~tg DNA). 
Lane a, DNA of  lymphocytes from peripheral blood; lane b, B lym- 
phocyte clone during proliferation phase II; lane c, T lymphocyte 
clone during proliferation phase lI; lanes d and e, immortalized, 
EBNA-negative B lymphoid cell clones; lanes fand g, immortal- 
ized, EBNA-negative T lymphoid cell clones; lane h, L929 cells; 
lane i, pEB-W DNA, digested with Barn HI (cloned EBV internal 
repeat sequence, Barn HI-fragment W) (6 pg; equivalent to about 
1 EBV internal repeat copy/cell or to about 0.1 EBV genome equiva- 
lent/cell). Eco Rl/Hind III fragments of L DNA served as molecu- 
lar weight standard. 
HTLV, types I and II, transform normal human lympho- 
cytes to infinite proliferation upon infection in vitro (29, 37). 
Although OKT4  + T  cells appear to be the most permissive 
cells, certain B lymphocytes (5) and nonlymphoid cells (6) 
can also be infected by HTLV. In the genome of  the lymphoid 
cells immortalized by L929 cytoplast fusion, we could not 
detect the HTLV-I or HTLV-II genome by Southern blot hy- 
bridization using the cloned 8.3-kbp Sstl-proviral fragment 
(pMT-2; HLTV-I) (37) and the 3.5-kbp Barn HI-proviral frag- 
ment (pMO1A; HTLV-II) (13), respectively, as probe. Plas- 
mid DNA (24 pg and 14 pg, respectively, equivalent to about 
one copy/cell) served as positive control. 
In addition we could not detect hybridization to the poly- 
oma virus genome in DNA of the immortalized cell lines 
using the cloned complete polyoma virus genome (pPB21) 
(12) as probe. 
These results suggest that EBV, HSV types 1 and 2, human 
CMV,  HTLV I  and II,  and polyoma virus may not be in- 
volved in the process of immortalization by fusion with L929 
cytoplasts. 
Mouse  cells  are  known  to  harbor  endogeneous  retro- 
viruses and to produce retroviruses under certain conditions. 
To check if the lymphoid cell lines immortalized by fusion 
with L929 cytoplasts produce retroviruses, we tested the ac- 
Discussion 
In this paper we describe the induction of  human lymphocyte 
proliferation by fusion with cytoplasts from mouse L929 
cells generating permanently growing lymphoid cell popula- 
tions of both B and T cell origin. These cell lines can be rou- 
tinely grown in vitro in serum-supplemented media and in 
chemically defined serum-free media  without addition of 
hemopoietic growth factors, suggesting that these cells possi- 
bly secrete their own growth factors. The cell lines have been 
maintained in culture for 1 yr (>/180 cell doublings) without 
any detection of growth arrest or senescence. We presume 
that  these  cell  lines  are  immortalized since  quiescent or 
lectin-stimulated human control lymphocytes  undergo senes- 
cence at day 3 or at day 10 in vitro, respectively, and human 
fibroblasts achieve ~50 cell doublings in culture. While the 
cell doubling time of 25-40 h is similar to other malignant 
lymphoid cell lines, these immortalized cells do not form 
colonies in soft agar medium (frequency ~<10  -5) and do not 
induce  tumors  upon  subcutaneous  injection of up  to  107 
cells in nude mice. 
Stable human B cell and T cell lines could be established 
by fusion with L929 cytoplasts and could be cloned by single 
cell cloning. These clones contained a nearly diploid set of 
human chromosomes. Murine chromosomes were regularly 
absent as revealed by centromere staining.  Neither a syste- 
matical loss of duplication of single human chromosomes, 
nor systematical rearrangements could be recorded. 
Cloned B cell lines produced human Ig with monoclonally 
restricted heavy chain classes and light chain types. Over a 
period of 4  mo B cell clones secreted continuously Ig in 
microgram quantities per  106 ceils.  These results  suggest 
that the immortalization method described will be useful in 
the generation of monoclonal human antibodies with pre- 
defined specificity. 
Earlier attempts to generate immortalized human immu- 
noglobulin-producing cells  involved the  fusion of human 
lymphoid cells with mouse myeloma cells (4). The interspe- 
cies hybridomas tended to  cease human  immunoglobulin 
production due to the selective loss of human chromosomes 
(9) or to disturbances of gene expression (35).  However, 
intraspecies  hybridomas  generated  by  fusion  of antigen- 
primed human B lymphocytes with EBV-transformed B lym- 
phoblastoid cell lines (40) secrete immunoglobulin molecules 
derived from both fusion partners (23), and the amount of 
immunoglobulin secreted can vary 100-fold among several 
clones (7). Our results show that human B lymphocytes im- 
mortalized by L929 cytoplast fusion give rise to cell lines that 
stably produce human homogeneous antibodies and do not 
express the malignant phenotype. 
Cytoplasts derived from transformed mouse L929 cells 
transfer an  immortalizing activity on quiescent or  lectin- 
prestimulated human B  and T  lymphocytes in contrast to 
cytoplasts  from  primary  mouse  embryo  fibroblasts  with 
limited life span. This suggests that the immortalization ac- 
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proliferation potential. 
Furthermore the L929 cytoplast fraction harbors  a mito- 
genie  activity  inducing  lymphocyte  proliferation phase  II 
5-15 d after cytoplasts/cell fusion. The cytoplasm act on both 
quiescent and lectin-prestimulated lymphocytes and are 20- 
fold more mitogenic for PWM-stimulated B cells than for T 
cells.  We only observed lymphocyte immortalization after 
the proliferation phase II had occurred, suggesting that this 
proliferation phase is a necessary step in the immortalization 
process. 
Because of the following findings we think it very unlikely 
that the immortalized cell lines were derived from whole so- 
matic cell hybrids:  (a) All lymphoid cell lines tested have a 
near diploid human karyotype.  (b)  The immortalized cell 
lines are lymphoid in origin since they grow in suspension, 
are recognized by monoclonal anti-human B cell or T cell 
antibodies, and produce homogeneous human immunoglob- 
ulins. Mouse L929 cells do not react with the anti-human 
B cell and T cell antibodies used. 
Conditioned medium of L929 cells failed to immortalize 
human  lymphocytes.  Cytoplast/cell  contact or PEG-medi- 
ated fusion of cytoplasts with cells is required to induce con- 
tinuous lymphocyte proliferation.  During the proliferation 
phase  II  some  of  the  competent  cells  fused  with  L929 
cytoplasts  gain an additional proliferation potential. At this 
time many  cells of finite life span  will continue to divide 
slowly. After more than 6 wk the fused cell population be- 
comes homogeneously clonogenic and steadily proliferative. 
Our observations based on light microscopy and [3Hlthymi- 
dine  incorporation  suggest  that  the  proliferation phase  II 
does not directly lead to immortalization but is followed by 
a crisis of proliferation. At least three hypothetical mecha- 
nisms can be envisaged to explain the results:  (a) A  mini- 
mum  number  of proliferation  initiations  transferred  by  a 
trans-acting  cytoplasmic factor of L929 cytoplasts  is needed 
for establishment of a lymphoid lineage. During the critical 
period of proliferation,  this factor(s)  must achieve a level 
sufficient  for immortalization,  and  suboptimal  concentra- 
tions of such a factor may instead result in transient cell acti- 
vation. (b) Alternatively initiation of proliferation may occur 
very frequently followed by reversions to normal senescent 
cells after some cell doublings.  Normal diploid cells may 
synthesize an inhibitor that blocks the initiation of DNA syn- 
thesis at the time the cell has completed its in vitro life span 
(38). During proliferation the synthesis of the inhibitor may 
be  repressed.  L929  cytoplasts  could harbor  a  factor  that 
maintains the repression of inhibitor genes of DNA synthesis 
or that alters the expression of inhibitor gene(s) or function- 
ally  neutralizes the inhibitor gene products in indefinitely 
proliferating  lymphocytes. (c) Alternatively genetic material 
may be transferred by cytoplast fusion from L929 cells into 
human  lymphocytes.  The  genome  of  several  mouse  en- 
dogeneous  DNA or RNA viruses  may induce lymphocyte 
proliferation and give rise to continuously growing cell lines. 
Due to our results described above we think it unlikely that 
the genome of EBV, HSV types 1 and 2, human CMV, HTLV 
I and II, or polyoma virus is transmitted to or induced in the 
recipient cells by L929 cytoplasts.  These viruses are proba- 
bly not involved in the induction of lymphocyte immortaliza- 
tion. In addition, no activity of reverse transcriptase  could 
be  detected  in  the  culture  supernatant  indicating  that no 
retroviruses are produced by the immortalized cell lines. 
Although  the  immortalizing  agent  transferred  by  L929 
cytoplasts  is unknown yet,  L929 cytoplast fusions may be 
used to generate a panel of  nontumorigenic human lymphoid 
cell lines of B and T cell origin for studies of lymphocyte het- 
erogeneity and function. 
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